1. Introduction {#sec1}
===============

Heart failure is an important cause of morbidity and mortality affecting more than 5 million individuals worldwide. Numerous advances, both pharmacological and non-pharmacological, have led to improved outcomes in patients with heart failure. Nearly 15--30% of patients with left ventricular (LV) systolic dysfunction have intraventricular conduction delays which leads to dyssynchronous ventricular contraction further compromising ventricular performance and systolic function.[@bib1], [@bib2] Cardiac resynchronization therapy which aims to synchronize ventricular activation and contraction has considerably improved both the mortality and morbidity in patients with LV systolic dysfunction.[@bib3], [@bib4] However, the response to cardiac resynchronization therapy in terms of improvements in LV systolic function and clinical symptoms is varied with nearly 30% being classified as non-responders. In contrast to this is a cohort of patients termed super-responders who demonstrate a dramatic response to cardiac resynchronization therapy (CRT) with considerable improvement in symptoms and near normalization of ejection fraction. However, clinical identifiers of this cohort of patients are still unclear.

The incidence of super-responders among Indian patients and their clinical characteristics has not been well described. We sought to identify the proportion of patients with a super-response to CRT among our patients undergoing CRT and to recognize clinical characteristics which identified this cohort of patients.

2. Materials and methods {#sec2}
========================

2.1. Study population {#sec2.1}
---------------------

This was a retrospective study performed in the Department of Cardiology at our center, including all patients undergoing CRT implantation by the author from 2011 to 2016. All patients undergoing CRT and with paired echocardiograms at 1 year apart were included in the study. CRT-P/CRT-D implantation was done in patients with a LV ejection fraction less than 35%, left bundle branch block (LBBB) on the electrocardiogram (ECG) with a QRS duration greater than 130 ms and in New York Heart Association (NYHA) class II/III/IV. LBBB was defined in accordance with previously defined criteria.[@bib5]

In patients with ischemic cardiomyopathy, LV ejection fraction and LV end systolic volumes/end diastolic volumes were measured by Simpson\'s method, while in patients with non-ischemic cardiomyopathy, they were measured using Simpson\'s method and/or Teichholz method. While the Simpson\'s method is the recommended echocardiographic gold standard for calculation of LV volumes, the Teichholz method was used in cases of technical difficulty in employing Simpson\'s method in patients with non-ischemic cardiomyopathy. Care was taken to ensure the same method was used for assessing LV volumes both at baseline and at 1 year follow-up.

The response to CRT was defined based on the reduction in LVESV at 1-year follow-up. A less than 15% decrease in LVESV was defined as a "non-response", a 15--30% decrease in LVESV was defined as a "response" while a greater than 30% decrease in LVESV was defined as a "super-response".[@bib6]

2.2. Statistical analysis {#sec2.2}
-------------------------

All data were collected prospectively and entered into a spreadsheet program (Microsoft Excel 2016™, Microsoft Corporation, Redmond, WA). Statistical analysis was done using the Statistical package for social sciences (SPSS Inc. version 23.0™, IBM Corporation, Chicago, IL). All continuous variables were summarized as mean ± standard deviation. Categorical variables were described as proportions and frequencies (%). The comparison between two groups for continuous variables was done by using the Student *t*-test. The comparison between two categorical variables was done by using the chi-square test or Fisher\'s exact test.

3. Results {#sec3}
==========

A total of 74 patients were identified who underwent CRT from 2011 to 2016. Of these, nine patients died within 1 year, and seven patients were lost to follow-up at the end of 1 year and were excluded from the analysis. A total of 58 patients were included in the final analysis ([Fig. 1](#fig1){ref-type="fig"}).Fig. 1Study population.Fig. 1

The mean age at device implantation was 62 ± 10.5 years. 51.7% (*n* = 30) of patients were males, while 48.3% (*n* = 28) were females. Dilated (non-ischemic) cardiomyopathy was the most common etiology accounting for 39 patients (67.2%), while ischemic cardiomyopathy was the etiology in 19 patients (32.8%). Of the 39 patients with non-ischemic cardiomyopathy, five patients had pacing induced cardiomyopathy from a previously implanted dual chamber pacemaker.

While a QRS duration greater than 130 ms was used as inclusion criteria for CRT, 74.1% (*n* = 43) of patients had a QRS duration greater than 140 ms and fulfilled the Strauss criteria for LBBB.[@bib7]

The mean LV ejection fraction at baseline was 26.3% ± 7%, while the mean LVESV and LVEDV were 136.6 ± 55.3 mL (ml) and 184.7 ± 52.3 ml, respectively.

The electrophysiologic separation of the LV lead from the right ventricular (RV) lead was assessed by measuring the LV -- RV interval on intracardiac electrograms. The mean LV -- RV interval was 86.8 ± 17.1 ms ([Table 1](#tbl1){ref-type="table"}).Table 1Baseline characteristics of study patients.Table 1Clinical characteristicsCRT (*n* = 58)Age (years)62 ± 10.5Sex Male30 (51.7) Female28 (48.3)Cardiac risk factors Diabetes mellitus18 (31) Hypertension18 (41.4) Smoking8 (17.4)Prior history of pacemaker insertion5 (8.6)Dilated cardiomyopathy39 (67.2)Ischemic cardiomyopathy19 (32.8)NYHA class II16 (27.5)NYHA class III39 (67.2)NYHA class IV3 (5.3)QRS duration \>140 msec43 (74.1)LV -- RV msec86.8 ± 17.1Ejection fraction (%)26.3 ± 7Left ventricular (LV) volume LVEDV (ml)184.7 ± 52.3 LVESV (ml)136.6 ± 55.3Secondary Mitral regurgitation None3 (5.2) Mild35 (60.3) Moderate13 (22.4) Severe7 (12.1)[^1][^2][^3]

Sixteen patients had a less than 15% reduction in LVESV and were classified as "non-responders", 26 patients had a 15--30% reduction in LVESV and were classified as "responders", while 16 patients had a greater than 30% reduction in LVESV and were classified as "super-responders" ([Table 2](#tbl2){ref-type="table"}, [Table 3](#tbl3){ref-type="table"}).Table 2Characteristics of non-responders, responders, and super-responders.Table 2Clinical characteristicsNon-responders (*n* = 16)Responders (*n* = 26)Super-Responders (*n* = 16)Age (years)59.8 ± 11.362.6 ± 10.162.2 ± 11Sex Male11 (68.8)13 (50)6 (37.5) Female5 (31.3)13 (50)10 (62.5)Diabetes mellitus6 (37.5)7 (26.9)5 (31.3)Hypertension3 (18.8)14 (53.8)7 (43.8)Dilated cardiomyopathy8 (50)16 (61.5)15 (93.8)Ischemic cardiomyopathy8 (50)10 (38.5)1 (6.2)LV -- RV (msec)91.5 ± 19.383.4 ± 1886.9 ± 17.2Percentage change in LVESV (ml)15 ± 17.423.8 ± 1367.1 ± 31.4Ejection fraction (%) Pre24.1 ± 3.627.5 ± 4.728.4 ± 5.2 Post27.1 ± 4.836.5 ± 650.1 ± 7.5 Change3 ± 2.69 ± 321.7 ± 6.7Change in NYHA class12 (75)26 (100)16 (100)HF-related hospitalization422Change in mitral regurgitation No change4 (25)7 (26.9)1 (6.3) Change by 1 grade11 (68.8)15 (57.7)12 (75) Change by 2 grades1 (6.3)3 (11.5)3 (18.8) Change by 3 grades01 (3.9)0[^4][^5][^6]Table 3Comparison of super-responders with non--super-responders.Table 3Clinical characteristicsSuper- Responders *n* = 16 (27.6%)Non-super-Responders *n* = 42 (72.4%)*p* valueAge (years)62.2 ± 1161.6 ± 9.6Sex Male6 (37.5)24 (57.1)0.18 Female10 (62.5)18 (42.9)Diabetes mellitus5 (31.3)13 (31)0.98Hypertension7 (43.8)17 (40.5)0.82Smoking06 (14.3)0.11Dilated Cardiomyopathy15 (93.7)24 (57.1)0.01Ischemic cardiomyopathy1 (6.3)18 (42.9)Prior RV pacing4 (25)1 (2.4)0.02Prior history of myocardial infarction014 (33.3)0.01[^7][^8][^9]

A higher proportion of super-responders were females (62.5% vs 32.9%; *p* -- 0.18). Fifteen of the 16 super-responders (93.7%) had non-ischemic cardiomyopathy, with four of these patients having pacing induced cardiomyopathy. Only one patient with ischemic cardiomyopathy had a super-response (1/19). Contrastingly, 18 of the 42 (42.9%) responders/non-responders had ischemic cardiomyopathy (93.7% vs 57.1%; *p* = 0.01).

A prior history of myocardial infarction was present in 14 responders/non-responders, while no super-responder had a history of myocardial infarction (33.3% vs 0%; *p* = 0.01).

Among the five patients with RV pacing induced cardiomyopathy, four had a super-response to CRT with near normalization of ejection fraction, while one patient was a responder with a 23% reduction in LVESV.

CRT may also result in significant improvements in mitral regurgitation (MR). In our patients, an improvement in MR by at-least one grade was seen in 46 patients (85.6%) ([Table 2](#tbl2){ref-type="table"}).

Clinical response to CRT was evaluated in terms of improvement in NYHA class. Four patients (25%) in the non-responder group, and all patients in the responder and super-responder groups had an improvement by at least one NYHA class. Heart failure--related hospitalization was seen in eight patients within the first year of implantation---four of these patients belonged to the non-responder group while two each were from the responder and super-responder groups.

4. Discussion {#sec4}
=============

Cardiac resynchronization therapy has a varied response with a success rate of 70% with nearly 30% of patients being classified as non-responders.[@bib8] At the other end of the spectrum is the subgroup of patients termed super-responders who have marked improvements in LV ejection fraction and reduction in LVESV. Various studies have identified a super-responder rate ranging from 10% to 30%.[@bib9], [@bib10]

In our study, we found a super-responder rate of 27.6% (*n* = 16). Non-ischemic cardiomyopathy, absence of a prior history of myocardial infarction and RV pacing--induced cardiomyopathy were predictors of a super-response to CRT. Nonischemic cardiomyopathy (NICM) appears to have a more favorable response to CRT than ischemic cardiomyopathy (ICM). Gasparini et al. in a study of 158 patients found a greater improvement in LVEF and reduction in NYHA class in patients with NICM compared with patients with ICM.[@bib11] This finding was subsequently confirmed in the subanalysis of several randomized studies[@bib12], [@bib13], [@bib14], [@bib15] emphasizing the importance of underlying substrate in predicting the response to CRT. We report a similar finding in our study with 93.7% of patients with a super-response having NICM.

Hsu et al. in a subanalysis of the Multicenter Automatic Defibrillator Implantation with Cardiac Resynchronization Therapy (MADIT-CRT) study reported the absence of a prior history of myocardial infarction as an independent predictor of a super-response to CRT, a finding also seen in our study. This likely reflects the absence of LV scar which could imply both, a greater amount of viable myocardium and the absence of scar in the region of LV lead implantation.[@bib10] One patient with ischemic cardiomyopathy in our cohort of patients had a super-response. This likely reflects the greater contribution of LV dyssynchrony, resulting from LBBB to LV dysfunction as compared with myocardial infarction and scarring.

Permanent RV pacing is a known cause of LV dysfunction resulting from the dyssynchrony induced by pacing. This cohort of patients have been shown to have an excellent response to CRT.[@bib16] In our study, all patients with pacing induced cardiomyopathy (*n* = 5) who underwent an upgrade to biventricular pacing had a good response to CRT. Biventricular pacing by ameliorating dyssynchrony restores the efficiency of cardiac contraction mechanics thus enabling recovery of LV function.

Females had a higher proportion of super-responders than males (62.5% vs 37.5%; *p* -- 0.18). Females have been reported to have higher rates of response to CRT compared with males previously.[@bib10] This has been postulated to be because of a higher prevalence of NICM and LBBB among females.[@bib17], [@bib18] In our study, there was no difference in the distribution of ischemic cardiomyopathy and NICM between males and females.

A discrepancy has been reported between CRT response as ascertained by clinical characteristics such as improvement in NYHA class and that determined by echocardiographic characteristics such as LVEF and LVESV. The higher response rate, when assessed using subjective parameters such as NYHA class and quality of life questionnaires, has been attributed either to improvements in MR or to a contributory placebo effect resulting from device implantation. In our study, 12 of the 16 non-responders had a change in NYHA class. All of these patients had a change in MR by at-least 1 grade which might explain the improvement in symptoms.

4.1. Limitations {#sec4.1}
----------------

Our study included only those patients who had paired echocardiograms at baseline and at 1 year follow-up. A total of nine deaths occurred in our cohort of patients before the completion of 1 year of follow-up, and these were not included in our analysis. Two of these patients had progressive heart failure, while the cause of death in the remaining seven patients could not be ascertained. The exclusion of these nine patients would constitute a bias as inclusion of these patients as non-responders would have resulted in a reduction in rates of response.

5. Conclusion {#sec5}
=============

While CRT has revolutionized the management of heart failure, a sizable proportion of patients do not show an adequate response. At the other end of the spectrum is a cohort of patients who demonstrate dramatic reverse remodeling. In our study, we found a super-response in 27.6% of patients. Underlying etiology is an important predictor with NICM having a better response than ICM. This is the first report of a super-response to CRT from the Indian subcontinent. Further studies need to be done to further characterize this response with a view to optimize patient selection for CRT.
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[^1]: Msec, milliseconds; ml, milliliter; CRT, cardiac resynchronization therapy; LVEDV, left ventricular end diastolic volume; LVESV, left ventricular end systolic volume.

[^2]: Categorical variables expressed as N (%).

[^3]: Continuous variables expressed as mean ± standard deviation.

[^4]: Msec, milliseconds; ml, milliliter; HF, heart failure.

[^5]: Categorical variables expressed as N (%).

[^6]: Continuous variables expressed as mean ± standard deviation.

[^7]: Msec, milliseconds; ml, milliliter; RV, right ventricular.

[^8]: Categorical variables expressed as N (%).

[^9]: Continuous variables expressed as mean ± standard deviation.
